Identification of Personalized Neoantigen Reactive TCRs from TIL and their Use in the Treatment of Patients with Cancer | Maria Parkhust, PhD

Maria Parkhust, PhD
Associate Scientist
NIH/NCI/Surgery Branch

Dr. Parkhurst earned a B.S. in Chemical Engineering from the University of Maryland and subsequently a Ph.D. in Chemical Engineering from the Johns Hopkins University. During her Ph.D. studies, she was awarded a Howard Hughes Medical Institute predoctoral fellowship and studied leukocyte migration in mucus and interaction with mucosal epithelia. She then completed a postdoctoral fellowship in the Surgery Branch of the NCI and worked on developing and monitoring T cell epitope vaccines. She then became a staff scientist in the Surgery Branch of the NCI at the manager of the Peptide Synthesis Core Facility. Since that time, the clinical pursuits of the Surgery Branch shifted from peptide vaccines to treating patients with adoptively transferred T lymphocytes. As such, Dr. Parkhurst is now the manager of the Antigen Discovery Core whose primary responsibilities are to generate new populations of tumor reactive T lymphocytes for adoptive transfer and TCRs for use in gene therapy clinical trials.

JOIN HERE!

Dr. Parkhust objectives:

• Explain what neoantigens are.
• Illustrate how neoantigen reactive T cells and T cell receptors can be identified.
• Analyze how T cells genetically modified to express neoantigen reactive TCRs can be used to treat patients with cancer.

FACULTY DISCLOSURE:

Dr. Parkhust  has indicated that she has no relevant financial relationships with commercial interests.

Planning Committee Disclosure

Dr. Lekakis has indicated that he has no relevant financial relationships with commercial interests.

Target Audience

Faculty, Primary Care Physicians, APRNs, PharmD

Accreditation

The University of Miami Leonard M. Miller School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation

The University of Miami Leonard M. Miller School of Medicine designates this live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.